{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:41:44Z","timestamp":1793745704491,"version":"4.6.1"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-022-02451-1","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T22:03:10Z","timestamp":1668722590000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Recent Advances on the Biological Study of Pharmaceutical Cocrystals"],"prefix":"10.1208","volume":"23","author":[{"given":"Zhipeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanhua","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"issue":"12","key":"2451_CR1","doi-asserted-by":"publisher","first-page":"7420","DOI":"10.1021\/acs.cgd.8b01898","volume":"19","author":"MAE Yousef","year":"2019","unstructured":"Yousef MAE, Vangala VR. Pharmaceutical co-crystals: molecules, crystals, formulations, medicines. Cryst Growth Des. 2019;19(12):7420\u201338.","journal-title":"Cryst Growth Des"},{"issue":"10","key":"2451_CR2","doi-asserted-by":"publisher","first-page":"6370","DOI":"10.1021\/acs.cgd.8b00933","volume":"18","author":"M Karimijafari","year":"2018","unstructured":"Karimijafari M, Padrela L, Walker G, Croker D. Creating cocrystals a review of pharmaceutical cocrystal preparation routes and applications. Cryst Growth Des. 2018;18(10):6370\u201387.","journal-title":"Cryst Growth Des"},{"issue":"5","key":"2451_CR3","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1021\/cg3002948","volume":"12","author":"S Aitipamula","year":"2012","unstructured":"Aitipamula S, Banerjee R, Bansal AK, Biradha K, Cheney ML, Choudhury AR, et al. Polymorphs, salts, and cocrystals: what\u2019s in a name? Cryst Growth Des. 2012;12(5):2147\u201352.","journal-title":"Cryst Growth Des"},{"issue":"1","key":"2451_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1021\/acs.cgd.6b01399","volume":"17","author":"LK Mapp","year":"2016","unstructured":"Mapp LK, Coles SJ, Aitipamula S. Design of cocrystals for molecules with limited hydrogen bonding functionalities: propyphenazone as a model system. Cryst Growth Des. 2016;17(1):163\u201374.","journal-title":"Cryst Growth Des"},{"issue":"4","key":"2451_CR5","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/jps.10100","volume":"91","author":"GGZ Zhang","year":"2002","unstructured":"Zhang GGZ, Gu C, Zell MT, Burkhardt RT, Munson EJ. Crystallization and transitions of sulfamerazine polymorphs. J Pharm Sci. 2002;91(4):1089\u2013100.","journal-title":"J Pharm Sci"},{"key":"2451_CR6","volume-title":"Solid-state chemistry of drugs","author":"SR Byrn","year":"1999","unstructured":"Byrn SR, Pfeiffer RR, Stowell JG. Solid-state chemistry of drugs. 2nd ed. West Lafayette (IN): SSCI Inc.; 1999.","edition":"2"},{"issue":"11","key":"2451_CR7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3390\/cryst9110553","volume":"9","author":"R Yutani","year":"2019","unstructured":"Yutani R, Haku R, Teraoka R, Tode C, Koide T, Kitagawa S, et al. Comparative evaluation of the photostability of carbamazepine polymorphs and cocrystals. Crystals. 2019;9(11):553\u201363.","journal-title":"Crystals"},{"key":"2451_CR8","first-page":"512","volume-title":"Encyclopedia of pharmaceutical technology","author":"N Rodriguez-Hornedo","year":"2013","unstructured":"Rodriguez-Hornedo N, Nehm SJ, Jayasanker A. Cocrystal: design, properties and formation mechanism. In: Swarbrick J, editor. Encyclopedia of pharmaceutical technology. 4th ed. New York: Informa Health Care; 2013. p. 512\u201330.","edition":"4"},{"key":"2451_CR9","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1211\/jpp.61.08.0001","volume":"61","author":"A Heinz","year":"2009","unstructured":"Heinz A, Strachan CJ, Gordon KC, Rades T. Analysis of solid state transformations of pharmaceutical compounds using vibrational spectroscopy. J Pharm Pharmacol. 2009;61:971\u201388.","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"2451_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v29.i3.10","volume":"29","author":"R Chadha","year":"2012","unstructured":"Chadha R, Saini A, Arora P, Bhandari S. Pharmaceutical cocrystals: a novel approach for oral bioavailability enhancement of drugs. Critical ReviewsTM in Therapeutic Drug Carrier Systems. 2012;29(3):183\u2013218.","journal-title":"Critical ReviewsTM in Therapeutic Drug Carrier Systems"},{"issue":"1","key":"2451_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/03639045.2016.1220568","volume":"43","author":"H Ahmed","year":"2017","unstructured":"Ahmed H, Shimpi MR, Velaga SP. Relationship between mechanical properties and crystal structure in cocrystals and salt of paracetamol. Drug Dev Ind Pharm. 2017;43(1):89\u201397.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"2451_CR12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1039\/D0CE01316A","volume":"23","author":"MKC Mannava","year":"2021","unstructured":"Mannava MKC, Gunnam A, Lodagekar A, Shastri NR, Nangia AK, Solomon KA. Enhanced solubility, permeability, and tabletability of nicorandil by salt and cocrystal formation. CrystEngComm. 2021;23(1):227\u201337.","journal-title":"CrystEngComm"},{"issue":"1","key":"2451_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1021\/acs.molpharmaceut.9b00377","volume":"17","author":"A Singaraju","year":"2020","unstructured":"Singaraju A, Bahl D, Wang C, Swenson D, Sun C, Stevens L. Molecular interpretation of the compaction performance and mechanical properties of caffeine cocrystals: a polymorphic study. Mol Pharm. 2020;17(1):21\u201331.","journal-title":"Mol Pharm"},{"issue":"11","key":"2451_CR14","doi-asserted-by":"publisher","first-page":"6135","DOI":"10.1021\/cg501310d","volume":"14","author":"NK Duggirala","year":"2014","unstructured":"Duggirala NK, Smith AJ, Wojtas \u0141, Shytle RD, Zaworotko MJ. Physical stability enhancement and pharmacokinetics of a lithium ionic cocrystal with glucose. Cryst Growth Des. 2014;14(11):6135\u201342.","journal-title":"Cryst Growth Des"},{"issue":"4","key":"2451_CR15","doi-asserted-by":"publisher","first-page":"e13066","DOI":"10.1111\/jfpe.13066","volume":"42","author":"TA Syed","year":"2019","unstructured":"Syed TA, Gaikar VG, Mukherjee S. Stability of co-crystals of caffeine with gallic acid in presence of coformers. J Food Process Eng. 2019;42(4):e13066.","journal-title":"J Food Process Eng"},{"issue":"8","key":"2451_CR16","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.1021\/acs.cgd.0c00749","volume":"20","author":"L Bofill","year":"2020","unstructured":"Bofill L, Sande DD, Barbas R, Prohens R. New cocrystal of ubiquinol with high stability to oxidation. Cryst Growth Des. 2020;20(8):5583\u20138.","journal-title":"Cryst Growth Des"},{"issue":"10","key":"2451_CR17","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.1021\/acs.cgd.0c01043","volume":"20","author":"C Guo","year":"2020","unstructured":"Guo C, Zhang Q, Zhu B, Zhang Z, Bao J, Ding Q, et al. Pharmaceutical cocrystals of nicorandil with enhanced chemical stability and sustained release. Cryst Growth Des. 2020;20(10):6995\u20137005.","journal-title":"Cryst Growth Des"},{"issue":"3","key":"2451_CR18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1039\/C0CE00772B","volume":"13","author":"VR Vangala","year":"2011","unstructured":"Vangala VR, Chow PS, Tan RBH. Characterization, physicochemical and photo-stability of a co-crystal involving an antibiotic drug, nitrofurantoin, and 4-hydroxybenzoic acid. CrystEngComm. 2011;13(3):759\u201362.","journal-title":"CrystEngComm"},{"issue":"7","key":"2451_CR19","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/cryst9070360","volume":"9","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Yang Z, Zhang S, Zhou X. Synthesis, crystal structure, and solubility analysis of a famotidine cocrystal. Crystals. 2019;9(7):360\u20139.","journal-title":"Crystals"},{"issue":"35","key":"2451_CR20","doi-asserted-by":"publisher","first-page":"6191","DOI":"10.1039\/D1CE00847A","volume":"23","author":"Y Wu","year":"2021","unstructured":"Wu Y, Hao X, Li J, Guan A, Zhou Z, Guo F. New insight into improving the solubility of poorly soluble drugs by preventing the formation of their hydrogen-bonds: a case of dapsone salts with camphorsulfonic and 5-sulfosalicylic acid. CrystEngComm. 2021;23(35):6191\u20138.","journal-title":"CrystEngComm"},{"issue":"8","key":"2451_CR21","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.1021\/acs.cgd.8b00603","volume":"18","author":"K Rajiv","year":"2018","unstructured":"Rajiv K, Pranita B, Bipul S. Trimorphic ethenzamide cocrystal: in vitro solubility and membrane efflux studies. Cryst Growth Des. 2018;18(8):4637\u201345.","journal-title":"Cryst Growth Des"},{"issue":"5","key":"2451_CR22","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1021\/mp500826y","volume":"12","author":"V Ferretti","year":"2015","unstructured":"Ferretti V, Dalpiaz A, Bertolasi V, Ferraro L, Beggiato S, Spizzo F, et al. Indomethacin co-crystals and their parent mixtures: does the intestinal barrier recognize them differently? Mol Pharmaceut. 2015;12(5):1501\u201311.","journal-title":"Mol Pharmaceut"},{"issue":"9","key":"2451_CR23","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.3390\/molecules26092677","volume":"26","author":"L Zhang","year":"2021","unstructured":"Zhang L, Kong D, Wang H, Jiao L, Zhao X, Song J, et al. Cocrystal of apixaban\u2013quercetin: improving solubility and bioavailability of drug combination of two poorly soluble drugs. Molecules. 2021;26(9):2677\u201393.","journal-title":"Molecules"},{"issue":"10","key":"2451_CR24","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3390\/pharmaceutics12100906","volume":"12","author":"S Ren","year":"2020","unstructured":"Ren S, Jiao L, Yang S, Zhang L, Song J, Yu H, et al. A novel co-crystal of bexarotene and ligustrazine improves pharmacokinetics and tissue distribution of bexarotene in SD rats. Pharmaceutics. 2020;12(10):906\u201325.","journal-title":"Pharmaceutics"},{"issue":"9","key":"2451_CR25","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.xphs.2019.04.017","volume":"108","author":"S Huang","year":"2019","unstructured":"Huang S, Xue Q, Xu J, Ruan S, Cai T. Simultaneously improving the physicochemical properties, dissolution performance, and bioavailability of apigenin and daidzein by co-crystallization with theophylline. J Pharm Sci. 2019;108(9):2982\u201393.","journal-title":"J Pharm Sci"},{"issue":"3","key":"2451_CR26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1021\/mp070001z","volume":"4","author":"AV Trask","year":"2007","unstructured":"Trask AV. An overview of pharmaceutical cocrystals as intellectual property. Mol Pharm. 2007;4(3):301\u20139.","journal-title":"Mol Pharm"},{"issue":"1","key":"2451_CR27","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/1359-6446(96)10039-8","volume":"11","author":"OH Chan","year":"1996","unstructured":"Chan OH, Stewart BH. Physicochemical and drug-delivery considerations for oral drug bioavailability. Drug Discov Today. 1996;11(1):461\u201373.","journal-title":"Drug Discov Today"},{"issue":"6","key":"2451_CR28","doi-asserted-by":"publisher","first-page":"S153","DOI":"10.36303\/SAJAA.2020.26.6.S3.2562","volume":"26","author":"F Rimmington","year":"2020","unstructured":"Rimmington F. Pharmacokinetics and pharmacodynamics. South Afr J Anaesth. 2020;26(6):S153\u20136.","journal-title":"South Afr J Anaesth"},{"key":"2451_CR29","volume-title":"Evaluation of drug candidates for preclinical development: pharmacokinetics, metabolism, pharmaceutics, and toxicology","author":"C Han","year":"2010","unstructured":"Han C, Davis CB, Wang B. Evaluation of drug candidates for preclinical development: pharmacokinetics, metabolism, pharmaceutics, and toxicology. New Jersey: John Wiley & Sons, Inc.; 2010."},{"issue":"1","key":"2451_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/cmdc.201800612","volume":"14","author":"BM Couillaud","year":"2019","unstructured":"Couillaud BM, Espeau P, Mignet N, Corvis Y. State of the art of pharmaceutical solid forms: from crystal property issues to nanocrystals formulation. ChemMedChem. 2019;14(1):8\u201323.","journal-title":"ChemMedChem"},{"issue":"1\u20132","key":"2451_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2011.07.037","volume":"419","author":"N Qiao","year":"2011","unstructured":"Qiao N, Li M, Schlindwein W, Malek N, Davies A, Trappitt G. Pharmaceutical cocrystals: an overview. Int J Pharmaceut. 2011;419(1\u20132):1\u201311.","journal-title":"Int J Pharmaceut"},{"issue":"5","key":"2451_CR32","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/cryst11050463","volume":"11","author":"J Tan","year":"2021","unstructured":"Tan J, Liu J, Ran L. A review of pharmaceutical nano-cocrystals: a novel strategy to improve the chemical and physical properties for poorly soluble drugs. Crystals. 2021;11(5):463\u201376.","journal-title":"Crystals"},{"issue":"4","key":"2451_CR33","doi-asserted-by":"publisher","first-page":"S522","DOI":"10.5530\/ijper.53.4s.147","volume":"53","author":"VD Vemuri","year":"2019","unstructured":"Vemuri VD, Lankalapalli S. Insight into concept and progress on pharmaceutical co-crystals: an overview. Indian J Pharm Educ. 2019;53(4):S522\u201338.","journal-title":"Indian J Pharm Educ"},{"issue":"42","key":"2451_CR34","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1039\/D0CE01276A","volume":"22","author":"P Roy","year":"2020","unstructured":"Roy P, Ghosh A. Progress on cocrystallization of poorly soluble NME\u2019s in the last decade. CrystEngComm. 2020;22(42):6958\u201374.","journal-title":"CrystEngComm"},{"issue":"11","key":"2451_CR35","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.3390\/molecules26113279","volume":"26","author":"I Nugrahani","year":"2021","unstructured":"Nugrahani I, Jessica MA. Amino acids as the potential co-former for co-crystal development: a review. Molecules. 2021;26(11):3279\u2013302.","journal-title":"Molecules"},{"key":"2451_CR36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejps.2014.01.009","volume":"57","author":"Y Tsume","year":"2014","unstructured":"Tsume Y, Mudie DM, Langguth P, Amidon GE, Amidon GL. The biopharmaceutics classification system: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. Eur J Pharm Sci. 2014;57:152\u201363.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"2451_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-76986-3","volume":"10","author":"SZ Mahmoudabadi","year":"2020","unstructured":"Mahmoudabadi SZ, Pazuki G. Investigation of COSMO-SAC model for solubility and cocrystal formation of pharmaceutical compounds. Sci Rep. 2020;10(1):1\u201314.","journal-title":"Sci Rep"},{"issue":"21","key":"2451_CR38","doi-asserted-by":"publisher","first-page":"12456","DOI":"10.1039\/D1CP00956G","volume":"23","author":"KV Drozd","year":"2021","unstructured":"Drozd KV, Manin AN, Voronin AP, Boycov DE, Churakov AV, Perlovich GL. A combined experimental and theoretical study of miconazole salts and cocrystals: crystal structures, DFT computations, formation thermodynamics and solubility improvement. Phys Chem Chem Phys. 2021;23(21):12456\u201370.","journal-title":"Phys Chem Chem Phys"},{"issue":"6","key":"2451_CR39","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1248\/bpb.b19-00048","volume":"42","author":"Y Suzuki","year":"2019","unstructured":"Suzuki Y, Muangnoi C, Thaweesest W, Teerawonganan P, Bhuket PRN, Titapiwatanakun V, et al. Exploring novel cocrystalline forms of oxyresveratrol to enhance aqueous solubility and permeability across a cell monolayer. Biol Pharm Bull. 2019;42(6):1004\u201312.","journal-title":"Biol Pharm Bull"},{"issue":"32","key":"2451_CR40","doi-asserted-by":"publisher","first-page":"4718","DOI":"10.1039\/C9CE00651F","volume":"21","author":"X Li","year":"2019","unstructured":"Li X, Yu G, Chen X, He L, Zhou Z, Ren Z. Investigating the solubilization effect of oxcarbazepine by forming cocrystals. CrystEngComm. 2019;21(32):4718\u201329.","journal-title":"CrystEngComm"},{"issue":"25","key":"2451_CR41","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1039\/D0CE00514B","volume":"22","author":"AO Surov","year":"2020","unstructured":"Surov AO, Vasilev NA, Voronin AP, Churakov AV, Emmerling F, Perlovich GL. Ciprofloxacin salts with benzoic acid derivatives: structural aspects, solid-state properties and solubility performance. CrystEngComm. 2020;22(25):4238\u201349.","journal-title":"CrystEngComm"},{"issue":"5","key":"2451_CR42","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3390\/pharmaceutics13050618","volume":"13","author":"H Kim","year":"2021","unstructured":"Kim H, Jang S, Kim IW. Enhanced dissolution of naproxen by combining cocrystallization and eutectic formation. Pharmaceutics. 2021;13(5):618\u201329.","journal-title":"Pharmaceutics"},{"issue":"5","key":"2451_CR43","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1021\/acs.molpharmaceut.5b00020","volume":"12","author":"P Sanphui","year":"2015","unstructured":"Sanphui P, Devi VK, Clara D, Malviya N, Ganguly S, Desiraju GR. Cocrystals of hydrochlorothiazide: solubility and diffusion\/permeability enhancements through drug\u2013conformer interactions. Mol Pharm. 2015;12(5):1615\u201322.","journal-title":"Mol Pharm"},{"issue":"9","key":"2451_CR44","first-page":"1","volume":"3","author":"J-W Seo","year":"2017","unstructured":"Seo J-W, Hwang K-M, Lee S-H, Kim D-W, Park E-S. Preparation and characterization of adefovir dipivoxil-stearic acid cocrystal with enhanced physicochemical properties. Pharm Dev Technol. 2017;3(9):1\u201330.","journal-title":"Pharm Dev Technol"},{"issue":"8","key":"2451_CR45","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1021\/acs.cgd.6b00552","volume":"16","author":"X Dai","year":"2016","unstructured":"Dai X, Li S, Chen J, Lu T. Improving the membrane permeability of 5-fluorouracil via cocrystallization. Cryst Growth Des. 2016;16(8):4430\u20138.","journal-title":"Cryst Growth Des"},{"issue":"4","key":"2451_CR46","doi-asserted-by":"publisher","first-page":"305","DOI":"10.15171\/bi.2018.33","volume":"8","author":"S Emami","year":"2018","unstructured":"Emami S, Siahi-Shadbad M, Adibkia K, Barzegar-Jalali M. Recent advances in improving oral drug bioavailability by cocrystals. BioImpacts. 2018;8(4):305\u201320.","journal-title":"BioImpacts"},{"issue":"8","key":"2451_CR47","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1002\/jps.24048","volume":"103","author":"Y Huang","year":"2014","unstructured":"Huang Y, Zhang B, Gao Y, Zhang J, Shi L. Baicalein-nicotinamide cocrystal with enhanced solubility, dissolution, and oral bioavailability. J Pharm Sci. 2014;103(8):2330\u20137.","journal-title":"J Pharm Sci"},{"issue":"7","key":"2451_CR48","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1021\/mp300169c","volume":"9","author":"DR Weyna","year":"2012","unstructured":"Weyna DR, Cheney ML, Shan N, Hanna M, Zaworotko MJ, Sava V, et al. Improving solubility and pharmacokinetics of meloxicam via multiple-component crystal formation. Mol Pharmaceut. 2012;9(7):2094\u2013102.","journal-title":"Mol Pharmaceut"},{"issue":"4","key":"2451_CR49","first-page":"403","volume":"49","author":"J Lin","year":"1997","unstructured":"Lin J, Lu A. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev. 1997;49(4):403\u201349.","journal-title":"Pharmacol Rev"},{"key":"2451_CR50","doi-asserted-by":"crossref","unstructured":"Modi NB. Pharmacokinetics and metabolism in drug discovery and preclinical development. In: Pharmacokinetics in Drug Discovery and Development. CRC Press; 2002. pp. 57\u201371.","DOI":"10.1201\/9781420010084.ch3"},{"issue":"7","key":"2451_CR51","doi-asserted-by":"publisher","first-page":"4612","DOI":"10.1021\/acs.cgd.0c00427","volume":"20","author":"J Haneef","year":"2020","unstructured":"Haneef J, Markad D, Chadha R. Interaction map driven cocrystallization of ambrisentan: structural and biopharmaceutical evaluation. Cryst Growth Des. 2020;20(7):4612\u201320.","journal-title":"Cryst Growth Des"},{"issue":"4","key":"2451_CR52","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1021\/acs.cgd.6b01863","volume":"17","author":"B Zhu","year":"2017","unstructured":"Zhu B, Zhang Q, Wang J, Mei X. Cocrystals of baicalein with higher solubility and enhanced bioavailability. Cryst Growth Des. 2017;17(4):1893\u2013901.","journal-title":"Cryst Growth Des"},{"issue":"1","key":"2451_CR53","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1021\/acs.cgd.7b00933","volume":"18","author":"P Goyal","year":"2017","unstructured":"Goyal P, Rani D, Chadha R. Crystal engineering: a remedy to tailor the biopharmaceutical aspects of glibenclamide. Cryst Growth Des. 2017;18(1):105\u201318.","journal-title":"Cryst Growth Des"},{"issue":"5","key":"2451_CR54","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1021\/acs.cgd.6b00266","volume":"16","author":"Y Chen","year":"2016","unstructured":"Chen Y, Li L, Yao J, Ma Y, Chen J, Lu T. Improving the solubility and bioavailability of apixaban via apixaban\u2013oxalic acid cocrystal. Cryst Growth Des. 2016;16(5):2923\u201330.","journal-title":"Cryst Growth Des"},{"issue":"22","key":"2451_CR55","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1039\/C6CC00975A","volume":"52","author":"K Suresh","year":"2016","unstructured":"Suresh K, Mannava CMK, Nangia A. Cocrystals and alloys of nitazoxanide: enhanced pharmacokinetics. Chem Commun. 2016;52(22):4223\u20136.","journal-title":"Chem Commun"},{"issue":"10","key":"2451_CR56","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1039\/C7CE02059G","volume":"20","author":"PA Corner","year":"2018","unstructured":"Corner PA, Berry DJ, McCabe JF, Barbas R, Prohens R, Du H, et al. Property prediction and pharmacokinetic evaluation of mixed stoichiometry cocrystals of zafirlukast, a drug delivery case study. CrystEngComm. 2018;20(10):1346\u201351.","journal-title":"CrystEngComm"},{"issue":"6","key":"2451_CR57","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1002\/jps.22434","volume":"100","author":"ML Cheney","year":"2011","unstructured":"Cheney ML, Weyna DR, Shan N, Hanna M, Wojtas L, Zaworotko MJ. Coformer selection in pharmaceutical cocrystal development: a case study of a meloxicam aspirin cocrystal that exhibits enhanced solubility and pharmacokinetics. J Pharm Sci. 2011;100(6):2172\u201381.","journal-title":"J Pharm Sci"},{"issue":"9","key":"2451_CR58","doi-asserted-by":"publisher","first-page":"3769","DOI":"10.1002\/jps.22181","volume":"99","author":"MK Stanton","year":"2010","unstructured":"Stanton MK, Kelly RC, Colletti A, Kiang YH, Langley M, Munson EJ, et al. Improved pharmacokinetics of AMG 517 through co-crystallization. Part 1: comparison of two acids with corresponding amide co-crystals. J Pharm Sci. 2010;99(9):3769\u201378.","journal-title":"J Pharm Sci"},{"issue":"5","key":"2451_CR59","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1021\/acs.cgd.6b01769","volume":"17","author":"K Vasisht","year":"2017","unstructured":"Vasisht K, Chadha K, Karan M, Bhalla Y, Chadha R, Khullar S, et al. Cocrystals of hesperetin: structural, pharmacokinetic, and pharmacodynamic evaluation. Cryst Growth Des. 2017;17(5):2386\u2013405.","journal-title":"Cryst Growth Des"},{"issue":"5","key":"2451_CR60","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3390\/molecules25051163","volume":"25","author":"N Xue","year":"2020","unstructured":"Xue N, Jia Y, Li C, He B, Yang C, Wang J. Characterizations and assays of alpha-glucosidase inhibition activity on gallic acid cocrystals: can the cocrystals be defined as a new chemical entity during binding with the alpha-glucosidase? Molecules. 2020;25(5):1163\u201375.","journal-title":"Molecules"},{"issue":"8","key":"2451_CR61","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1039\/C5CE01899D","volume":"18","author":"K Vasisht","year":"2016","unstructured":"Vasisht K, Chadha K, Karan M, Bhalla Y, Jena AK, Chadha R. Enhancing biopharmaceutical parameters of bioflavonoid quercetin by cocrystallization. CrystEngComm. 2016;18(8):1403\u201315.","journal-title":"CrystEngComm"},{"issue":"37","key":"2451_CR62","doi-asserted-by":"publisher","first-page":"15994","DOI":"10.1039\/D0NJ03033C","volume":"44","author":"Y Yu","year":"2020","unstructured":"Yu Y, Yu M, Wang L, Li Y, Wu Z, Yan C. A supramolecular adduct of tegafur and syringic acid: the first tegafur-nutraceutical cocrystal with perfected in vitro and in vivo characteristics as well as synergized anticancer activities. New J Chem. 2020;44(37):15994\u20136005.","journal-title":"New J Chem"},{"issue":"9\u201310","key":"2451_CR63","first-page":"118942","volume":"574","author":"S Tomar","year":"2019","unstructured":"Tomar S, Chakraborti S, Jindal A, Grewal MK, Chadha R. Cocrystals of diacerein: towards the development of improved biopharmaceutical parameters. Int J Pharmaceut. 2019;574(9\u201310):118942.","journal-title":"Int J Pharmaceut"},{"issue":"30","key":"2451_CR64","doi-asserted-by":"publisher","first-page":"5010","DOI":"10.1039\/D0CE00713G","volume":"22","author":"L Wang","year":"2020","unstructured":"Wang L, Wang L, Yu Y, Li Y, Wu Z, Yan C. Cocrystallization of 5-fluorouracil and l-phenylalanine: the first zwitterionic cocrystal of 5-fluorouracil with amino acid exhibiting perfect in vitro\/vivo pharmaceutical properties. CrystEngComm. 2020;22(30):5010\u201321.","journal-title":"CrystEngComm"},{"issue":"8","key":"2451_CR65","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1039\/D1AN00171J","volume":"146","author":"Y Yu","year":"2021","unstructured":"Yu Y, Niu Y, Wang L, Li Y, Wu Z, Yan C. Supramolecular self-assembly and perfected in vitro\/vivo property of 5-fluorouracil and ferulic acid on the strength of double optimized strategy: the first 5-fluorouracial-phenolic acid nutraceutical cocrystal with synergistic antitumor efficacy. Analyst. 2021;146(8):2506\u201319.","journal-title":"Analyst"},{"issue":"45","key":"2451_CR66","doi-asserted-by":"publisher","first-page":"7992","DOI":"10.1039\/D0CE01297A","volume":"22","author":"Y Yu","year":"2020","unstructured":"Yu Y, Wang L, Bu F, Wang L, Li Y, Wang C, et al. The supramolecular self-assembly of 5-fluorouracil and caffeic acid through cocrystallization strategy opens up a new way for the development of synergistic antitumor pharmaceutical cocrystal. CrystEngComm. 2020;22(45):7992\u20138006.","journal-title":"CrystEngComm"},{"issue":"10","key":"2451_CR67","first-page":"1","volume":"2020","author":"D Xu","year":"2020","unstructured":"Xu D, Zhang G, Zhang T, Jin B, Ma C. Pharmacokinetic comparisons of naringenin and naringenin-nicotinamide cocrystal in rats by LC-MS\/MS. J Anal Methods Chem. 2020;2020(10):1\u201310.","journal-title":"J Anal Methods Chem"},{"issue":"4","key":"2451_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/6685806","volume":"2021","author":"M Wasim","year":"2021","unstructured":"Wasim M, Mannan A, Asad MHHB, Amirzada MI, Shafique M, Hussain I. Fabrication of carbamazepine cocrystals: characterization, in vitro and comparative in vivo evaluation. Biomed Res Int. 2021;2021(4):1\u20139.","journal-title":"Biomed Res Int"},{"issue":"10","key":"2451_CR69","doi-asserted-by":"publisher","first-page":"3930","DOI":"10.1039\/C9NJ06180K","volume":"44","author":"L Wang","year":"2020","unstructured":"Wang L, Yu Y, Jiang F, Li Y, Wu Z, Yan C. The first zwitterionic cocrystal of indomethacin with amino acid showing optimized physicochemical properties as well as accelerated absorption and slowed elimination in vivo. New J Chem. 2020;44(10):3930\u20139.","journal-title":"New J Chem"},{"issue":"1","key":"2451_CR70","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s12247-020-09428-2","volume":"16","author":"J Thimmasetty","year":"2021","unstructured":"Thimmasetty J, Ghosh T, Nayak NS, Raheem A. Oral bioavailability enhancement of paliperidone by the use of cocrystalization and precipitation inhibition. J Pharm Innov. 2021;16(1):160\u20139.","journal-title":"J Pharm Innov"},{"issue":"2","key":"2451_CR71","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/10837450.2019.1687521","volume":"25","author":"II Soliman","year":"2020","unstructured":"Soliman II, Kandil SM, Abdou EM. Gabapentin\u2013saccharin co-crystals with enhanced physicochemical properties and in vivo absorption formulated as oro-dispersible tablets. Pharm Dev Technol. 2020;25(2):227\u201336.","journal-title":"Pharm Dev Technol"},{"issue":"2","key":"2451_CR72","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ajps.2018.04.009","volume":"14","author":"J Pi","year":"2019","unstructured":"Pi J, Wang S, Li W, Kebebe D, Zhang Y, Zhang B, et al. A nano-cocrystal strategy to improve the dissolution rate and oral bioavailability of baicalein. Asian J Pharm Sci. 2019;14(2):154\u201364.","journal-title":"Asian J Pharm Sci"},{"issue":"59","key":"2451_CR73","doi-asserted-by":"publisher","first-page":"36125","DOI":"10.1039\/D0RA06608G","volume":"10","author":"L Li","year":"2020","unstructured":"Li L, Yin X, Diao K. Improving the solubility and bioavailability of anti-hepatitis B drug PEC via PEC\u2013fumaric acid cocrystal. RSC Adv. 2020;10(59):36125\u201334.","journal-title":"RSC Adv"},{"issue":"3","key":"2451_CR74","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/03639045.2021.1892744","volume":"47","author":"K Fatima","year":"2021","unstructured":"Fatima K, Bukhari NI, Latif S, Afzal H, Hussain A, Shamim R, et al. Amelioration of physicochemical, pharmaceutical, and pharmacokinetic properties of lornoxicam by cocrystallization with a novel coformer. Drug Dev Ind Pharm. 2021;47(3):498\u2013508.","journal-title":"Drug Dev Ind Pharm"},{"issue":"3","key":"2451_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12249-019-1324-0","volume":"20","author":"W Cui","year":"2019","unstructured":"Cui W, He Z, Zhang Y, Fan Q, Feng N. Naringenin cocrystals prepared by solution crystallization method for improving bioavailability and anti-hyperlipidemia effects. AAPS PharmSciTech. 2019;20(3):1\u201312.","journal-title":"AAPS PharmSciTech"},{"issue":"10","key":"2451_CR76","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.2174\/1568026033452096","volume":"3","author":"J Lin","year":"2003","unstructured":"Lin J, Sahakian DC, De Morais SMF, Xu JJ, Polzer RJ, Winter SM. The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr Top Med Chem. 2003;3(10):1125\u201354.","journal-title":"Curr Top Med Chem"},{"issue":"2","key":"2451_CR77","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1177\/019262339502300202","volume":"23","author":"J Caldwell","year":"1995","unstructured":"Caldwell J, Gardner I, Swales N. An introduction to drug disposition: the basic principles of absorption, distribution, metabolism, and excretion. Toxicol Pathol. 1995;23(2):102\u201314.","journal-title":"Toxicol Pathol"},{"issue":"5","key":"2451_CR78","first-page":"753","volume":"21","author":"JC Stevens","year":"1993","unstructured":"Stevens JC, Shipley LA, Cashman JR, Vandenbranden M, Wrighton SA. Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities. Drug Metab Dispos. 1993;21(5):753\u201360.","journal-title":"Drug Metab Dispos"},{"issue":"57","key":"2451_CR79","doi-asserted-by":"publisher","first-page":"103487","DOI":"10.1016\/j.etap.2020.103487","volume":"80","author":"H Wang","year":"2020","unstructured":"Wang H, Li S, Liu L, Wang J, Wang Y, Guo W. Interactions between dipfluzine-based complexes and cytochrome p450 enzymes: information on salt, cocrystal, and salt cocrystal complexes. Environ Toxicol Phar. 2020;80(57):103487.","journal-title":"Environ Toxicol Phar"},{"issue":"10","key":"2451_CR80","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1248\/cpb.c20-00212","volume":"68","author":"C Li","year":"2020","unstructured":"Li C, Du P, Zhou M, Yang L, Zhang H, Wang J, et al. Spectroscopic methodology and molecular docking studies on changes in binding interaction of felodipine with bovine serum albumin induced by cocrystallization with \u03b2-resorcylic acid. Chem Pharm Bull. 2020;68(10):946\u201353.","journal-title":"Chem Pharm Bull"},{"issue":"3","key":"2451_CR81","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s11095-013-1181-6","volume":"31","author":"Y Lin","year":"2014","unstructured":"Lin Y, Yang H, Yang C, Wang J. Preparation, characterization, and evaluation of dipfluzine\u2013benzoic acid co-crystals with improved physicochemical properties. Pharm Res. 2014;31(3):566\u201378.","journal-title":"Pharm Res"},{"issue":"4","key":"2451_CR82","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1021\/acs.cgd.9b00137","volume":"19","author":"X Pan","year":"2019","unstructured":"Pan X, Zheng Y, Chen R, Qiu S, Chen Z, Rao W, et al. Cocrystal of sulfamethazine and p-aminobenzoic acid: structural establishment and enhanced antibacterial properties. Cryst Growth Des. 2019;19(4):2455\u201360.","journal-title":"Cryst Growth Des"},{"issue":"90","key":"2451_CR83","doi-asserted-by":"publisher","first-page":"49070","DOI":"10.1039\/C4RA03207A","volume":"4","author":"R Saha","year":"2014","unstructured":"Saha R, Sengupta S, Dey SK, Steele IM, Bhattacharyya A, Biswas S, et al. A pharmaceutical cocrystal with potential anticancer activity. RSC Adv. 2014;4(90):49070\u20138.","journal-title":"RSC Adv"},{"key":"2451_CR84","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jpba.2016.10.020","volume":"134","author":"R Chadha","year":"2017","unstructured":"Chadha R, Bhalla Y, Nandan A, Chadha K, Karan M. Chrysin cocrystals: characterization and evaluation. J Pharmaceut Biomed. 2017;134:361\u201371.","journal-title":"J Pharmaceut Biomed"},{"issue":"3","key":"2451_CR85","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/14328917.2016.1200843","volume":"21","author":"P Sathya","year":"2016","unstructured":"Sathya P, Vidyalaksmi Y, Pugazhendhi S, Gopalakrishnan R. Benzotriazole p-hydroxybenzoic acid: physicochemical and biological evaluation of an organic cocrystal. Mater Res Innov. 2016;21(3):182\u20138.","journal-title":"Mater Res Innov"},{"issue":"5","key":"2451_CR86","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1021\/acs.cgd.0c00301","volume":"20","author":"OO Abosede","year":"2020","unstructured":"Abosede OO, Gordon AT, Dembaremba TO, Lorentino CMA, Frota HF, Santos ALS, et al. Trimesic acid\u2013theophylline and isopthalic acid\u2013caffeine cocrystals: synthesis, characterization, solubility, molecular docking, and antimicrobial activity. Cryst Growth Des. 2020;20(5):3510\u201322.","journal-title":"Cryst Growth Des"},{"issue":"10","key":"2451_CR87","doi-asserted-by":"publisher","first-page":"6796","DOI":"10.1021\/acs.cgd.0c00900","volume":"20","author":"O Shemchuk","year":"2020","unstructured":"Shemchuk O, d\u2019Agostino S, Fiore C, Sambri V, Zannoli S, Grepioni F, et al. Natural antimicrobials meet a synthetic antibiotic: carvacrol\/thymol and ciprofloxacin cocrystals as a promising solid-state route to activity enhancement. Cryst Growth Des. 2020;20(10):6796\u2013803.","journal-title":"Cryst Growth Des"},{"issue":"4","key":"2451_CR88","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1021\/acs.cgd.9b01570","volume":"20","author":"F Jubeen","year":"2020","unstructured":"Jubeen F, Liaqat A, Amjad F, Sultan M, Iqbal SZ, Sajid I, et al. Synthesis of 5-fluorouracil cocrystals with novel organic acids as coformers and anticancer evaluation against HCT-116 colorectal cell lines. Cryst Growth Des. 2020;20(4):2406\u201314.","journal-title":"Cryst Growth Des"},{"key":"2451_CR89","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fchem.2019.00092","volume":"7","author":"M Nicolov","year":"2019","unstructured":"Nicolov M, Ghiulai RM, Voicu M, Mioc M, Duse AO, Roman R, et al. Cocrystal formation of betulinic acid and ascorbic acid: synthesis, physico-chemical assessment, antioxidant, and antiproliferative activity. Front Chem. 2019;7:92.","journal-title":"Front Chem"},{"key":"2451_CR90","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejps.2016.04.030","volume":"89","author":"DR Serrano","year":"2016","unstructured":"Serrano DR, Persoons T, D\u2019Arcy DM, Galiana C, Dea-Ayuela MA, Healy AM. Modelling and shadowgraph imaging of cocrystal dissolution and assessment of in vitro antimicrobial activity for sulfadimidine\/4-aminosalicylic acid cocrystals. Eur J Pharm Sci. 2016;89:125\u201336.","journal-title":"Eur J Pharm Sci"},{"key":"2451_CR91","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jddst.2017.01.005","volume":"38","author":"MF Arafa","year":"2017","unstructured":"Arafa MF, El-Gizawy SA, Osman MA, El Maghraby GM. Co-crystallization for enhanced dissolution rate of nateglinide: in vitro and in vivo evaluation. J Drug Deliv Sci Tec. 2017;38:9\u201317.","journal-title":"J Drug Deliv Sci Tec"},{"issue":"4","key":"2451_CR92","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1208\/s12249-019-1360-9","volume":"20","author":"MK Gautam","year":"2019","unstructured":"Gautam MK, Besan M, Pandit D, Mandal S, Chadha R. Cocrystal of 5-fluorouracil: characterization and evaluation of biopharmaceutical parameters. AAPS PharmSciTech. 2019;20(4):149\u201365.","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"2451_CR93","first-page":"321","volume":"84","author":"K Kanakaraju","year":"2014","unstructured":"Kanakaraju K, Lavanya V, Nangia A. Temozolomide cocrystals exhibit drug sensitivity in glioblastoma cells. P Natl A Sci India A. 2014;84(2):321\u201330.","journal-title":"P Natl A Sci India A"},{"key":"2451_CR94","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jpba.2017.11.028","volume":"149","author":"SSA Abidi","year":"2018","unstructured":"Abidi SSA, Azim Y, Khan SN, Khan AU. Sulfaguanidine cocrystals: synthesis, structural characterization and their antibacterial and hemolytic analysis. J Pharmaceut Biomed. 2018;149:351\u20137.","journal-title":"J Pharmaceut Biomed"},{"issue":"12","key":"2451_CR95","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1093\/jac\/dkz391","volume":"74","author":"GYN Varma","year":"2019","unstructured":"Varma GYN, Kummari G, Paik P, Kalle AM. Celecoxib potentiates antibiotic uptake by altering membrane potential and permeability in Staphylococcus aureus. J Antimicrob Chemoth. 2019;74(12):3462\u201372.","journal-title":"J Antimicrob Chemoth"},{"issue":"20","key":"2451_CR96","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1039\/D0CE00226G","volume":"22","author":"N Tabassum","year":"2020","unstructured":"Tabassum N, Varras PC, Arshad F, Choudhary MI, Yousuf S. Biological activity tuning of antibacterial urotropine via co-crystallization: synthesis, biological activity evaluation and computational insight. CrystEngComm. 2020;22(20):3439\u201350.","journal-title":"CrystEngComm"},{"issue":"7","key":"2451_CR97","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMra052270","volume":"354","author":"VJ Navarro","year":"2006","unstructured":"Navarro VJ, Senior JR. Drug-related hepatotoxicity. New Engl J Med. 2006;354(7):731\u20139.","journal-title":"New Engl J Med"},{"issue":"5","key":"2451_CR98","first-page":"233","volume":"2","author":"A Pandit","year":"2012","unstructured":"Pandit A, Sachdeva T, Bafna P. Drug-induced hepatotoxicity: a review. J Appl Pharm Sci. 2012;2(5):233\u201343.","journal-title":"J Appl Pharm Sci"},{"issue":"6","key":"2451_CR99","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/j.1440-1843.2006.00941.x","volume":"11","author":"WW Yew","year":"2006","unstructured":"Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology. 2006;11(6):699\u2013707.","journal-title":"Respirology"},{"issue":"9","key":"2451_CR100","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1080\/14740338.2016.1194824","volume":"15","author":"V Bruno","year":"2016","unstructured":"Bruno V, Grazia A, Mariella SC, Giovanna C, Leakos M, Daniele S, et al. Drug-induced hepatotoxicity in cancer patients-implication for treatment. Expert Opin Drug Saf. 2016;15(9):1219\u201338.","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"2451_CR101","doi-asserted-by":"publisher","first-page":"466","DOI":"10.7150\/ijbs.5.466","volume":"5","author":"HI El-Sayyad","year":"2009","unstructured":"El-Sayyad HI, Ismail MF, Shalaby FM, Abou-El-Magd RF, Gaur RL, Fernando A, et al. Histopathological effects of cisplatin, doxorubicin and 5-flurouracil (5-fu) on the liver of male albino rats. Int J Biol Sci. 2009;5(5):466\u201373.","journal-title":"Int J Biol Sci"},{"issue":"2","key":"2451_CR102","doi-asserted-by":"publisher","first-page":"187","DOI":"10.5604\/01.3001.0010.8633","volume":"17","author":"L Meunier","year":"2018","unstructured":"Meunier L, Larrey D. Recent advances in hepatotoxicity of non steroidal anti-inflammatory drugs. Ann Hepatol. 2018;17(2):187\u201391.","journal-title":"Ann Hepatol"},{"issue":"4","key":"2451_CR103","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.cld.2013.07.009","volume":"17","author":"A Unzueta","year":"2013","unstructured":"Unzueta A, Vargas HE. Nonsteroidal anti-inflammatory drug\u2013induced hepatoxicity. Clin Liver Dis. 2013;17(4):643\u201356.","journal-title":"Clin Liver Dis"},{"issue":"2","key":"2451_CR104","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S1089-3261(03)00022-9","volume":"7","author":"NC Teoh","year":"2003","unstructured":"Teoh NC, Farrell GC. Hepatotoxicity associated with non-steroidal anti-inflammatory drugs. Clin Liver Dis. 2003;7(2):401\u201313.","journal-title":"Clin Liver Dis"},{"issue":"7","key":"2451_CR105","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1021\/acs.cgd.8b00576","volume":"18","author":"F Liu","year":"2018","unstructured":"Liu F, Wang L, Li Y, Wu Z, Yan C. Protective effects of quercetin against pyrazinamide induced hepatotoxicity via a cocrystallization strategy of complementary advantages. Cryst Growth Des. 2018;18(7):3729\u201333.","journal-title":"Cryst Growth Des"},{"issue":"2","key":"2451_CR106","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1021\/acs.cgd.7b01514","volume":"18","author":"B Yadav","year":"2018","unstructured":"Yadav B, Balasubramanian S, Chavan RB, Thipparaboina R, Naidu VGM, Shastri NR. Hepatoprotective cocrystals and salts of riluzole: prediction, synthesis, solid state characterization, and evaluation. Cryst Growth Des. 2018;18(2):1047\u201361.","journal-title":"Cryst Growth Des"},{"issue":"9","key":"2451_CR107","doi-asserted-by":"publisher","first-page":"5161","DOI":"10.1021\/acs.cgd.9b00541","volume":"19","author":"B Yadav","year":"2019","unstructured":"Yadav B, Gunnam A, Thipparaboina R, Nangia AK, Shastri NR. Hepatoprotective cocrystals of isoniazid: synthesis, solid state characterization, and hepatotoxicity studies. Cryst Growth Des. 2019;19(9):5161\u201372.","journal-title":"Cryst Growth Des"},{"issue":"3","key":"2451_CR108","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1021\/acs.molpharmaceut.9b01178","volume":"17","author":"F Martin","year":"2020","unstructured":"Martin F, Pop M, Kacso I, Grosu IG, Micla\u0306u\u015f M, Vodnar D, et al. Ketoconazole-p-aminobenzoic acid cocrystal: revival of an old drug by crystal engineering. Mol Pharmaceut. 2020;17(3):919\u201332.","journal-title":"Mol Pharmaceut"},{"key":"2451_CR109","doi-asserted-by":"publisher","first-page":"105216","DOI":"10.1016\/j.ejps.2020.105216","volume":"144","author":"F Liu","year":"2020","unstructured":"Liu F, Wang L, Yu M, Li Y, Wu Z, Yan C. A new cocrystal of isoniazid-quercetin with hepatoprotective effect: the design, structure, and in vitro\/in vivo performance evaluation. Eur J Pharm Sci. 2020;144:105216.","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"2451_CR110","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1080\/03639045.2020.1764024","volume":"46","author":"F Liu","year":"2020","unstructured":"Liu F, Jiang F, Li Y, Liu R, Wu Z, Yan C. Cocrystallization with syringic acid presents a new opportunity for effectively reducing the hepatotoxicity of isoniazid. Drug Dev Ind Pharm. 2020;46(6):988\u201395.","journal-title":"Drug Dev Ind Pharm"},{"issue":"Special","key":"2451_CR111","doi-asserted-by":"publisher","first-page":"SP49","DOI":"10.2131\/jts.41.SP49","volume":"41","author":"I Horii","year":"2016","unstructured":"Horii I. The principle of safety evaluation in medicinal drug-how can toxicology contribute to drug discovery and development as a multidisciplinary science? J Toxicol Sci. 2016;41(Special):SP49-67.","journal-title":"J Toxicol Sci"},{"key":"2451_CR112","unstructured":"Klaassen CD. Toxicology: the basic science of poisons. 7th & 8th Edition. New York: McGraw-Hill.; 2008."},{"key":"2451_CR113","doi-asserted-by":"publisher","first-page":"127842","DOI":"10.1016\/j.molstruc.2020.127842","volume":"1207","author":"M Muresan-Pop","year":"2020","unstructured":"Muresan-Pop M, Chereches G, Borodi G, Fischer-Fodor E, Simon S. Structural characterization of 5-fluorouracil & piperazine new solid forms and evaluation of their antitumor activity. J Mol Struct. 2020;1207:127842.","journal-title":"J Mol Struct"},{"issue":"2","key":"2451_CR114","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1021\/acs.cgd.9b01365","volume":"20","author":"SK Rai","year":"2020","unstructured":"Rai SK, Gunnam A, Mannava M, Nangia AK. Improving the dissolution rate of anticancer drug dabrafenib. Cryst Growth Des. 2020;20(2):1035\u201346.","journal-title":"Cryst Growth Des"},{"issue":"42","key":"2451_CR115","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1039\/D0CE01276A","volume":"22","author":"P Roy","year":"2020","unstructured":"Roy P, Ghosh A. Progress on cocrystallization of poorly soluble NME\u2019s in the last decade. CrystEngComm. 2020;22(42):6958\u201374.","journal-title":"CrystEngComm"},{"issue":"12","key":"2451_CR116","first-page":"736","volume":"43","author":"N Kovacich","year":"2018","unstructured":"Kovacich N, Candidate PD, Chavez B. Ertugliflozin (steglatro): a new option for SGLT2 inhibition. P & T. 2018;43(12):736\u201342.","journal-title":"P & T"},{"issue":"12","key":"2451_CR117","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s40262-017-0543-3","volume":"56","author":"S Ayalasomayajula","year":"2017","unstructured":"Ayalasomayajula S, Langenickel T, Pal P, Boggarapu S, Sunkara G. Clinical pharmacokinetics of sacubitril\/valsartan (LCZ696): a novel angiotensin receptor-neprilysin inhibitor. Clin Pharmacokinet. 2017;56(12):1461\u201378.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"2451_CR118","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.clinthera.2021.04.002","volume":"43","author":"J Cebrecos","year":"2021","unstructured":"Cebrecos J, Carlson JD, Encina G, Lahjou M, Sans A, Sust M, et al. Celecoxib-tramadol co-crystal: a randomized 4-way crossover comparative bioavailability study. Clin Ther. 2021;43(6):1051\u201365.","journal-title":"Clin Ther"},{"key":"2451_CR119","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.molstruc.2018.07.079","volume":"1173","author":"S Suresh Kumar","year":"2018","unstructured":"Suresh Kumar S, Athimoolam S, Sridhar B. Structural, spectral, theoretical and anticancer studies on new co-crystal of the drug 5-fluorouracil. J Mol Struct. 2018;1173:951\u20138.","journal-title":"J Mol Struct"},{"key":"2451_CR120","first-page":"1","volume":"00","author":"R Langford","year":"2022","unstructured":"Langford R, Morte A, Sust M, Cebrecos J, Vaqu\u00e9 A, Ortiz E, et al. Efficacy and safety of co-crystal of tramadol-celecoxib (CTC) in acute moderate-to-severe pain after abdominal hysterectomy: a randomized, double-blind, phase 3 trial (STARDOM2). Eur J Pain. 2022;00:1\u201314.","journal-title":"Eur J Pain"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-022-02451-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-022-02451-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-022-02451-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T18:08:15Z","timestamp":1669658895000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-022-02451-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":120,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["2451"],"URL":"https:\/\/doi.org\/10.1208\/s12249-022-02451-1","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]},"assertion":[{"value":"12 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"303"}}